REPL
Replimune Group, Inc.
7.28
USD
This page is just a preview of the data found in TrendSpider’s full version
Replimune Group, Inc. stock is down -34.47% since 30 days ago. The next earnings date is Feb 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 10 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 07 Nov 20:28 | 17 Nov, 2023 | 12.50 | 7871 | ||
| 07 Nov 20:28 | 17 Nov, 2023 | 12.50 | 7871 | ||
| 07 Nov 20:29 | 17 Nov, 2023 | 12.50 | 7871 | ||
| 08 Nov 16:38 | 16 Feb, 2024 | 10.00 | 160 | ||
| 17 Nov 16:05 | 17 Nov, 2023 | 12.50 | 3935 | ||
| 05 Dec 20:44 | 16 Feb, 2024 | 12.50 | 1903 | ||
| 05 Dec 20:48 | 16 Feb, 2024 | 12.50 | 1903 | ||
| 06 Dec 14:30 | 16 Feb, 2024 | 12.50 | 1903 | ||
| 06 Dec 17:21 | 16 Feb, 2024 | 12.50 | 1903 | ||
| 06 Dec 19:45 | 16 Feb, 2024 | 12.50 | 1903 |
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer.
